Open in interactive viewer → charts, metric popovers & call review

Mesa Labs Serves the Promised Dinner — With One Plate Still Cold

First-ever full-year guide, a $5M net cost cut and a $40M buyback — set against a sterilization fix that is only mostly finished, and a stock that has already given back 10% from its October high.
MLAB · Earnings Call · 2026-11-09

The Promise Was Precision. The Answer Was "Mixed."

In August, new CEO Siddhartha Kadia told investors the second quarter was "the appetizer" and that the dinner — full-year guidance alongside first-half results — would arrive in November. It arrived. But the centerpiece of his August agenda, a promised clear read on whether the sterilization and disinfection control franchise was durably fixed, came back deliberately hedged. On most product lines, he said, the manufacturing problems behind the delays are resolved and lines now ship on a schedule customers can plan around; the FDA inspected the Bozeman facility in September and issued no observations.

The durable fix is in place for most of the franchise It is not yet in the place for all of it.

Siddhartha Chandrakant Kadia, CEO · 2026-11-09
One product line — the one carrying the largest share of the past due backlog — is only partially resolved, and he called it the single biggest priority in the business. That is the honest read, and it matters because the headline number flatters it: SDC grew 14.6% organically in the quarter, but most of that is lapping last year's comparison delivery delays. The fuller lenses — trailing-twelve-month revenue of $104 million, up 8.5% and the highest in the franchise's history, and about 5% first-half growth — are the ones to hold him to.

Guidance Built to Be Beaten, Not Admired

This is the substantive change in the story. After a first call in August in which Kadia explicitly declined to talk numbers — “we are not going to provide any color on the guidance itself right now” — Siddhartha Kadia, CEO · 2026-08-10 — Mesa now guides fiscal 27 revenue of $250–255 million and adjusted EBITDA of $66–68 million against roughly $63 million in fiscal 26. That is 5–8% EBITDA growth on 0–2% revenue growth: earnings power growing several times faster than the top line, with a savings plan doing real work underneath. The catch sits in the cadence. Third-quarter revenue is guided roughly flat year over year, because the clinical genomics reset steps revenue down, the reinvestment spend front-runs the savings, and last year's fourth quarter was exceptional as SDC flushed a large chunk of backlog. Analyst Matt Stanton pressed exactly this point. “I built this guidance conservatively on purpose.” — Siddhartha Chandrakant Kadia, CEO · 2026-11-09 A CEO who would rather under-promise in his first hundred days is not new information; a CEO who does it with a full year of numbers and a defined measure — adjusted EBITDA, the metric tied to his PSUs and his credit facility — is a different level of commitment. The balance sheet is the quiet confirmation. Leverage was 1.85 turns in August with a stated goal of 1.75 to 1.5 by fiscal year-end; “our goal over the remainder of the fiscal year is to drive that down somewhere between 1.75x and 1.5x” — John Sakys, CFO · 2026-08-10 — and here we are at 1.75x with two quarters to spare, after $20.1 million of net debt repayment in the first half. Effective net cash of −$35 million is improving from −$49 million a year ago, and liabilities to assets have fallen to 55%, down 5.4 points year over year. There is also a non-operating lever management flagged: a reasonable possibility of partially releasing the US valuation allowance within twelve months, which would flatter the 28.1% effective tax rate.

Clinical Genomics: Shrinking on Purpose

The loudest keyword of the quarter is the one being shrunk. Clinical genomics revenue fell 8.8%, and the October 13 restructuring — approximately $9.3 million of annualized operating cost out, roughly $4.3 million reinvested into commercial capacity and corporate roles, $5 million net — is the first capital-allocation decision of the new regime. The logic is clean: keep pharmacogenomics and oncology, keep accounts that run the mass array at scale, and let low-margin revenue go so gross profit dollars can rise even as the top line falls. The proof point Kadia leans on is a good one. All three of the largest clinical genomics customers have renewed, for two to three and a half years, and the largest — the large customer that also carries China exposure — signed the longest term at approximately 25% of that business. What he would not do is commit on ownership: “No decisions been made about the portfolio itself.” — Siddhartha Chandrakant Kadia, CEO · 2026-11-09 Read that as an option deliberately kept open. Stanton's follow-up — why hold a dilutive asset at all — is the question that will recur until the business proves it generates cash.

The Reframing That Actually Matters

The most under-appreciated item on the call was structural, not financial. Kadia has stopped describing four segments and started describing two pairs: quality control businesses (SDC plus calibration solutions, $77.2 million of first-half revenue at 66.4% combined gross profit) and life science tools businesses (biopharmaceutical development plus clinical genomics, $45.3 million at 61%). That is a capital-allocation map dressed as a taxonomy: quality control is the acquisition engine, through bringing distributors in house and then small tuck-ins; tools build internally, around the next-generation Gyrolab platform due in fiscal 28. This is a genuine reversal of framing. Paul Knight's opening question in August was premised on the old Mesa — “this has historically been a company focused on some merger and acquisition activity” — Paul Knight, Analyst · 2026-08-10 — and the CEO then told him acquisitions were not the near-term priority. Now there is a sequence, a board-approved size discipline, and a $40 million buyback authorization through December 2028 to absorb capital while the debt comes down. The company is also, pointedly, not chasing tools assets: full valuations, larger scale, contested processes. Biopharmaceutical development, meanwhile, is timing rather than demand. Revenue fell 8.2% organically on export control processing delays on in-hand orders and shipments that missed the quarter close by days: “Those orders were in hand and shipped by mid October.” — Siddhartha Chandrakant Kadia, CEO · 2026-11-09 Verifiable next quarter, which makes it a fair test. The market context cuts against the story in an instructive way. life science tools has been one of the stronger clusters in the tape over the past ninety days, with Thermo, Danaher, Bio-Rad and Repligen among the advancers — but that strength is in scaled, profitable tool franchises, and Mesa's tools half is precisely the part being restructured. The group is being rewarded for what Mesa is still building. The tape itself is ambivalent. Mesa is up 13.3% across the 63 sessions into this report, yet sits 10.1% below its October 5 peak of $142.23 — a rally that lost its nerve before the dinner was served. For a $715 million company issuing its first full-year guide, with revenue up just 1% year over year in the latest filed quarter and gross margin at 64.9%, up 2.8 points, the next two quarters are a simple exam: does the one unresolved product line come back, do the slipped BPD orders show up, and does the savings plan land in the cost base? The story has stopped being about promises and started being about arithmetic.